Teva Pharmaceutical's Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. See why I ...

Teva Pharmaceutical Industries TEVA reported fourth-quarter 2024 adjusted earnings of 71 cents per share, which beat the ...

We recently published a list of These 10 Stocks Were Wednesday’s Worst Performers. In this article, we are going to take a ...

Teva Pharmaceutical Industries reported a slightly larger than expected rise in fourth-quarter profit, helped by double-digit ...

An upstart biopharma firm founded by two former executives at CinCor Pharma – which celebrated a $1.8B exit to AstraZeneca in ...

Teva Pharmaceutical Industries Limited’s TEVA share price has dipped by 13.89%, which has investors questioning if this is ...

Teva reported fourth-quarter revenue of $4.2 billion, beating analyst estimates of $4.13 billion, according to Benzinga Pro.

"2024 marked a transformative year for Teva, resulting in a second consecutive year of growth, driven by our generic products ...

Teva Pharmaceutical Industries Ltd. (TEVA) has seen a decline of 13.92 percent in its stock value during Wednesday afternoon trading ...

Barclays lowered the firm’s price target on Teva (TEVA) to $26 from $28 and keeps an Overweight rating on the shares. The post-earnings selloff ...

Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Teva ...

Israeli generics giant Teva Pharmaceutical Industries today reported results for the year and the quarter ended December 31, ...